Patents by Inventor Ekaterina Klimatcheva

Ekaterina Klimatcheva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CXCL13 antibodies and methods of using the same
    Patent number: 11981730
    Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: May 14, 2024
    Assignee: Vaccinex, Inc.
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
  • ANTI-CXCL13 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20210087263
    Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
    Type: Application
    Filed: September 24, 2020
    Publication date: March 25, 2021
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
  • Polynucleotides encoding anti-CXCL13 antibodies
    Patent number: 10829550
    Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: November 10, 2020
    Assignee: Vaccinex, Inc.
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
  • ANTI-CXCL13 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20180244764
    Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
    Type: Application
    Filed: April 13, 2018
    Publication date: August 30, 2018
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
  • Anti-CXCL13 antibodies and methods of using the same
    Patent number: 9963504
    Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: May 8, 2018
    Assignee: Vaccinex, Inc.
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
  • ANTI-CXCL13 ANTIBODIES AND ASSOCIATED EPITOPE SEQUENCES
    Publication number: 20160002325
    Abstract: The invention relates to epitopes of CXCL13 and to binding agents, such as antibodies, that specifically bind to CXCL13.
    Type: Application
    Filed: March 8, 2013
    Publication date: January 7, 2016
    Applicant: Vaccinex, Inc.
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
  • ANTI-CXCL13 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20150050287
    Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
    Type: Application
    Filed: September 1, 2011
    Publication date: February 19, 2015
    Applicant: VACCINEX, INC.
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith
  • ANTI-CXCL13 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20140147447
    Abstract: Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.
    Type: Application
    Filed: September 1, 2011
    Publication date: May 29, 2014
    Applicant: VACCINEX, INC.
    Inventors: Ekaterina Klimatcheva, Mark Paris, Ernest S. Smith